Education
About Us
Working with TipRanks
Follow Us
Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD
GLMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $23.80
Previous CloseN/A
Volume19.24K
Average Volume (3M)301.28K
Market Cap
$3.50M
Enterprise Value-$13.29M
Total Cash (Recent Filing)$15.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.60
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,258,034
10 Day Avg. Volume143,633
30 Day Avg. Volume301,283
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-3.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit160.10
Enterprise Value/Ebitda2.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesTargeting international markets where semaglutide is not meaningfully patent-protected presents significant market opportunities for Galmed.
Partnerships And CollaborationsGalmed has partnered with Virginia Commonwealth University to evaluate Aramchol’s potential in oncology indications.
Bears Say
Clinical Development DelaysThe program is still relatively early stage and there will not be human clinical data until 1H26.
Financial ChallengesGalmed may also potentially require a capital raise to commence a clinical trial, and under current market conditions, financing will likely be difficult and significantly dilutive.
Galmed Pharmaceuticals News
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $1.15 and its highest was $23.80 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is $3.50M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is May 20, 2026 which is in 272 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 2,258,034 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in GLMD
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutic solutions to address liver diseases. The company's primary product candidate, Aramchol, is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Galmed Pharmaceuticals operates within the biotechnology and pharmaceutical sectors, with its research and development efforts aimed at addressing unmet medical needs in the area of liver health.
Technical Analysis
Ownership Overview
6.20%
Insiders
0.15% Mutual Funds
<0.01% Other Institutional Investors
99.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---